RIGL
Rigel Pharmaceuticals Inc
47.20$
+0.4%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 4.5% | 10.6% | 6.9% | 7.6% | 14.5% | 10.1% | 8.3% | 4.4% | 6.8% | 8.5% | 7.8% | 10.8% | 8.6% | |
| 95.5% | 89.4% | 93.1% | 92.4% | 85.5% | 89.9% | 91.7% | 95.6% | 93.2% | 91.5% | 92.2% | 89.2% | 91.4% | |
| 23.0% | 8.9% | 20.4% | 15.0% | 11.2% | 9.8% | 15.8% | 6.7% | 10.6% | 15.3% | 19.9% | 17.7% | 15.8% | |
| 88.3% | 73.5% | 96.3% | 76.1% | 48.9% | 51.3% | 52.0% | 28.8% | 41.7% | 43.0% | 52.1% | 41.5% | 44.2% | |
| 111.4% | 83.9% | 116.7% | 91.2% | 60.1% | 61.0% | 67.8% | 35.5% | 52.2% | 58.3% | 72.0% | 59.2% | 59.9% | |
| -15.9% | 5.5% | -23.6% | 1.2% | 25.4% | 28.9% | 23.9% | 60.1% | 40.9% | 33.2% | 20.2% | 30.0% | 31.5% | |
| 6.7% | 5.3% | 6.3% | 5.5% | 3.7% | 3.4% | 3.5% | 1.8% | 2.7% | 2.4% | 2.4% | 1.0% | 2.1% | |
| -20.2% | 2.1% | -27.9% | -2.8% | 22.5% | 26.4% | 21.6% | 59.0% | 39.8% | 32.5% | 19.8% | 30.0% | 30.9% | |
| 2.4% | 1.9% | 1.2% | – | – | 1.5% | 0.1% | 0.4% | -0.4% | -351.5% | 5.1% | 8.0% | -85.4% | |
| -20.2% | 2.1% | -27.9% | -2.8% | 22.5% | 24.9% | 21.5% | 58.6% | 40.2% | 384.0% | 14.7% | 22.0% | 116.3% | |
| -12.4% | 8.2% | -20.2% | 4.4% | 27.3% | 30.9% | 26.2% | 61.4% | 43.4% | 35.8% | 23.3% | 32.0% | 34.0% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.